Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, as highlighted in a recent voluntary announcement. The company's application for clinical trials of TQB6411, an EGFR/cMet Bispecific ADC, has been accepted by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. Additionally, TQB2922, an EGFR/cMet Bispecific Antibody, has entered Phase I trials, while TQB3002, a Fourth-Generation EGFR Inhibitor, received approval for clinical trials from the United States Food and Drug Administration (FDA) in November of the previous year. These advancements underscore the company's commitment to innovation and its ongoing efforts to enhance its pipeline of clinical-stage assets with First-In-Class and Best-In-Class potential.